Interestingly, preliminary results from the phase II study of the PD-1 inhibitor pembrolizumab in soft tissue sarcomas showed signs of efficacy in UPS not observed for other sarcoma subtypes, possibly implicating a particularly important role for immunosuppression in UPS tumorigenesis. This evidence concerns the gene PDCD1 and sarcoma.